Tvardi Therapeutics, Inc.
Tvardi Therapeutics, Inc. (TVRD) Stock Overview
Explore Tvardi Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
213.9M
P/E Ratio
-4.65
EPS (TTM)
$-2.25
ROE
2.27%
TVRD Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Tvardi Therapeutics, Inc. (TVRD) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 43.69, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of N/A.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -4.65 and a market capitalization of 213.9M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Technical Indicators
Analyst Recommendations
Price Targets
Company Profile
Tvardi Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. Their lead candidate, TTI-101, is currently in Phase 2 clinical trials for idiopathic pulmonary fibrosis (IPF) and hepatocellular carcinoma (HCC).
Imran Alibhai
17
2450 Holcombe Blvd, Suite X, Sugar Land, TX
2025